Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert

This article was originally published in The Tan Sheet

Executive Summary

FDA should allow researchers more flexibility to evaluate consumers’ purchase decisions in self-selection studies for OTC drugs, according to contract research organization PEGUS Research.

You may also be interested in...



Statin Label Change Stirs OTC Switch Discussions

FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.

Statin Label Change Stirs OTC Switch Discussions

FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.

Merck Mines Mevacor Switch Data To Press FDA On Self-Selection Stance

Purchase decisions in OTC switch self-selection studies offer insight into subjects’ thinking “and how they might act in a real-world pharmacy setting,” Merck tells FDA in response to a draft guidance that says such decisions are driven by cost and are “an unreliable surrogate” for self-selection.

Related Content

Topics

UsernamePublicRestriction

Register

PS105319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel